Similar articles for PMID: 17698862

Year	Number of Results
1971	1
1988	1
1989	1
1993	3
1994	2
1995	1
1996	2
1997	2
1998	2
1999	9
2000	2
2001	8
2002	17
2003	9
2004	11
2005	11
2006	11
2007	14
2008	12
2009	21
2010	27
2011	10
2012	19
2013	41
2014	44
2015	44
2016	23
2017	20
2018	25
2019	16
2020	13
2021	8
2022	7
2024	0

1

Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?

Hanauer SB. Hanauer SB. Gut. 2007 Sep;56(9):1181-3. doi: 10.1136/gut.2006.115980. Gut. 2007. PMID: 17698862 Free PMC article.

2

Anti-TNF therapy in inflammatory bowel diseases: a huge review.

Peyrin-Biroulet L. Peyrin-Biroulet L. Minerva Gastroenterol Dietol. 2010 Jun;56(2):233-43. Minerva Gastroenterol Dietol. 2010. PMID: 20485259 Review.

3

Review article: Infliximab therapy for inflammatory bowel disease--seven years on.

Rutgeerts P, Van Assche G, Vermeire S. Rutgeerts P, et al. Aliment Pharmacol Ther. 2006 Feb 15;23(4):451-63. doi: 10.1111/j.1365-2036.2006.02786.x. Aliment Pharmacol Ther. 2006. PMID: 16441465 Free article. Review.

4

[Biological therapy as treatment of inflammatory bowel diseases].

Agnholt J. Agnholt J. Ugeskr Laeger. 2008 Jun 9;170(24):2152-6. Ugeskr Laeger. 2008. PMID: 18565302 Danish.

5

Immunosuppression in inflammatory bowel disease: traditional, biological or both?

Van Assche G, Vermeire S, Rutgeerts P. Van Assche G, et al. Curr Opin Gastroenterol. 2009 Jul;25(4):323-8. doi: 10.1097/MOG.0b013e32832c073a. Curr Opin Gastroenterol. 2009. PMID: 19417645 Review.

6

Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy.

Sokol H, Seksik P, Carrat F, Nion-Larmurier I, Vienne A, Beaugerie L, Cosnes J. Sokol H, et al. Gut. 2010 Oct;59(10):1363-8. doi: 10.1136/gut.2010.212712. Epub 2010 Jun 29. Gut. 2010. PMID: 20587545

7

Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.

Caprilli R, Angelucci E, Cocco A, Viscido A, Annese V, Ardizzone S, Biancone L, Castiglione F, Cottone M, Meucci G, Paoluzi P, Papi C, Sturniolo GC, Vecchi M. Caprilli R, et al. Dig Liver Dis. 2005 Jun;37(6):407-17. doi: 10.1016/j.dld.2004.12.013. Dig Liver Dis. 2005. PMID: 15893279 Review.

8

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?

D'Haens GR, Panaccione R, Higgins PD, Vermeire S, Gassull M, Chowers Y, Hanauer SB, Herfarth H, Hommes DW, Kamm M, Löfberg R, Quary A, Sands B, Sood A, Watermeyer G, Lashner B, Lémann M, Plevy S, Reinisch W, Schreiber S, Siegel C, Targan S, Watanabe M, Feagan B, Sandborn WJ, Colombel JF, Travis S. D'Haens GR, et al. Am J Gastroenterol. 2011 Feb;106(2):199-212; quiz 213. doi: 10.1038/ajg.2010.392. Epub 2010 Nov 2. Am J Gastroenterol. 2011. PMID: 21045814 Review.

9

Conventional treatment in inflammatory bowel disease--recent trends. Immunosuppressants and biologic agents: should they or need they be used together? How to use immunosuppressive therapy better (and safer) tomorrow?

Leung Y, Hanauer SB. Leung Y, et al. Gastroenterol Clin Biol. 2009 Jun;33 Suppl 3:S202-8. doi: 10.1016/S0399-8320(09)73155-0. Gastroenterol Clin Biol. 2009. PMID: 20117343 Free article.

10

Update on idiopathic colitides.

Strobel S, Abreu MT. Strobel S, et al. Curr Opin Gastroenterol. 2013 Jan;29(1):60-5. doi: 10.1097/MOG.0b013e32835abc93. Curr Opin Gastroenterol. 2013. PMID: 23207597 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

400 results

Results by year